MSJ

We are committed to provide our readers with leading information on all aspects of MS, NMO and related autoimmune diseases of the central nervous system.

[MSJ @MSJ_Research]

Our journals are part of the international community of
@ECTRIMS @ACTRIMS @PACTRIMS_admin @lactrims_org and @eurims

You can read our articles on:
Multiple Sclerosis Journal https://t.co/Z2zC18ZbVk
MSJ Experimental Translational and Clinical https://t.co/XSjbuKwfiR

[MSJ @MSJ_Research]

Vascular risk factors may contribute to increased disability, motor impairment, and region-specific sensorimotor network structural integrity in #MultipleSclerosis.

Sutdy from @AlbergoniMatteo @NRU_SanRaffaele @MyUniSR @SanRaffaeleMI ▶️ https://t.co/MkWmTJTzD8

[MSJ @MSJ_Research]

Certain sex-dependent bioactive lipid mediator, such as 9-HOTrE, may display neuroprotective effects in #MultipleSclerosis.

🔓 MSJ-ETC study from @MScentrum020 @amsterdamumc ▶️ https://t.co/GZhBmzPk9J

[MSJ @MSJ_Research]

Most risk factors, including family history, HLA-DRB1*15:01, EBNA1 antibody levels, smoking and low sun exposure, were associated with both late- and adult-onset #MultipleSclerosis, suggesting a shared etiology.

Study from @karolinskainst ▶️ https://t.co/vEPNeOESUl

[MSJ @MSJ_Research]

There were no significant difference in retinal atrophy (GCIPL or pRNFL) and clinical outcomes between extended versus standard interval natalizumab therapy in #MultipleSclerosis.

🔓MSJ-ETC study from @JohnsHopkins ▶️ https://t.co/2RQynJyuR5

[ECTRIMS @ECTRIMS]

🔍 Is it time to revisit how we describe the course of #multiplesclerosis?

A new IACCTMS paper in @Nature Reviews Neurology sets out a roadmap towards a more biologically informed approach to describing #MS — one that better reflects our evolving understanding of the disease.

We thank the international experts involved for their continued commitment to advancing how MS is understood, studied and treated.

🌍 IACCTMS is jointly supported by @ECTRIMS and the @mssociety.

📖 Read the paper: https://t.co/84etXhvZd3

[MSJ @MSJ_Research]

Enterovirus infection in B-cell depleted patients may cause severe central nervous system involvement, and early IVIg and investigational antivirals may be considered.

Narrative review with two illustrative cases from @AKunchok @ClevelandClinic ▶️ https://t.co/J6b3HoA2Nu

[MSJ @MSJ_Research]

Real-world practice in Sweden broadly aligns with national recommendations for pregnancy in #MultipleSclerosis, with widespread use of rituximab reflecting its perceived safety and durable effect

🔓MSJ-ETC study from @karolinskainst ▶️ https://t.co/pyT31EwkZ2

[MSJ @MSJ_Research]

Post-traumatic stress disorder in people with #MultipleSclerosis and its impact on activity, employment and participation.

A narrative review from @DavidEFreedman @UofTPsych @UnityHealthTO ▶️ https://t.co/D8bexDvSNl

[MSJ @MSJ_Research]

Insights from the @DK_MS_Registry following nationwide implementation of patient-reported outcomes in #MultipleSclerosis across different ages and disability levels.

🔓MSJ-ETC study from @melindamagyari @Rigshospitalet @uni_copenhagen ▶️ https://t.co/CN2WQN3ryC

[MSJ @MSJ_Research]

Two years of short-course cladribine tablets provided sustained clinical and cognitive benefits, supporting the potential for treatment-free remission in relapsing #MultipleSclerosis.

Results from the MAGNIFY-MS Extension study from
@unisiena @UNSW ▶️ https://t.co/bAfHmwPvb9

[MSJ @MSJ_Research]

An unrecorded interval between #MultipleSclerosis onset and initial data in observational studies (left-truncation). can affect relapse estimates and, less so, disability outcomes.

Study from @TheRMH ▶️ https://t.co/LdBcFLos6C

[MSJ @MSJ_Research]

🔊 Listen to Mehari Woldemariam Merid @MelbourneOf on the mediation effect of DNA methylation on the associations of Mediterranean diet scores with #MultipleSclerosis onset-risk.

📄 And read the full manuscript ▶️ https://t.co/XizytGjfxu

[Dr. Kaarina Kowalec 🧬👩‍🔬 @KaarinaKowalec]

https://t.co/AJaTyDd6xi

[Dr. Kaarina Kowalec 🧬👩‍🔬 @KaarinaKowalec]

New paper 🧬 We piloted saliva collection for genetics in the NARCOMS MS registry: ~62% of interested participants consented; only ~10% of invited actually took part. Hypothetical willingness to share genetic data ≠ actual behavior. 🔗https://t.co/JnzrLvhesK @MSJ_Research

[MSJ @MSJ_Research]

📢August issue is now available
🔽
https://t.co/R9gufw3TDl

...and the cover goes to @karolinskainst with therr susceptibility network analysis of disease trajectories leading to #MultipleSclerosis ▶️ https://t.co/QsGuChZuGd

[Dr. Kaarina Kowalec 🧬👩‍🔬 @KaarinaKowalec]

New paper in @MSJ_Research from our lab:🧬1 in 20 people with MS on dimethyl fumarate develop severe lymphopenia. We found a polygenic score for lymphocyte counts predicts risk (57% risk reduction per SD increase). Genetics may help flag who needs closer monitoring.

[MSJ @MSJ_Research]

Adding the digital health application (levidex) levidex to treatment as usual yielded meaningful improvements in depressive symptoms and social/work functioning in people with #MultipleSclerosis.

LAMONT trial ▶️ https://t.co/msUjm8MkET

[MSJ @MSJ_Research]

A three-miRNA panel (hsa-miR-122-5p, hsa-miR-15b-5p, hsa-miR-30e-5p) demonstrated high discriminative accuracy for relapses and remissions in treatment-naive #MultipleSclerosis.

Study from @TelAvivUni ▶️ https://t.co/3MOI0Cscbi

[MSJ @MSJ_Research]

Rituximab may be inferior to ocrelizumab for relapse suppression (ARR 0.05 vs 0.03), though the rarity of relapses underpowered comparisons.

Study from @UAlberta @UBC ▶️ https://t.co/0E82eOOGwV

[MSJ @MSJ_Research]

Three automated platforms for blood glial fibrillary acidic protein #GFAP -Quanterix Simoa HD-X, Roche Elecsys and Fujirebio Lumipulse G600- showed strong correlations and minor biases in controls and #MultipleSclerosis.

Study from @UKSH_KI_HL ▶️ https://t.co/Ufda4EBBJS